ONO2506 clinical trials
Also written ONO-2506PO and ONO-2506.
How each study uses ONO2506 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2004 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Ono Pharmaceutical Co. Ltd (3) · Ono Pharma USA Inc (2) · Ono Pharmaceutical Co., Ltd. (1) · Merck Sharp & Dohme LLC (1)
Studies
Open first, then newest update. How each study uses ONO2506 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)TerminatedPhase 2Merck Sharp & Dohme LLCNCT00401310Written as Comparator: MK0724How we know
- Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in JapanCompletedPhase 2Ono Pharmaceutical Co., Ltd.NCT00212693Written as ONO-2506POHow we know
- A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic StrokeTerminatedPhase 2/3Ono Pharma USA IncNCT00046761Written as ONO-2506How we know
- Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2Ono Pharmaceutical Co. LtdNCT00403104Written as ONO-2506POHow we know
- A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2Ono Pharmaceutical Co. LtdNCT00694941Written as ONO-2506POHow we know
- Effects of ONO-2506PO in Patients With Alzheimer's DiseaseCompletedPhase 2Ono Pharma USA IncNCT00083421Written as ONO-2506POHow we know
- Study of ONO-2506 in Patients With Acute Ischemic StrokeCompletedPhase 2/3Ono Pharmaceutical Co. LtdNCT00229177Written as ONO-2506How we know